Pharma BD Deal Intelligence

Johnson & Johnson / Centocor Inc.

1999 · Acquisition/Merger · $4.9B · Complete

Announcement Sentiment

100

Strongly positive

Outcome Score

Worked — the deal delivered on its rationale.

Johnson & Johnson acquired Centocor in a $4.9 billion stock-for-stock transaction, gaining full ownership of Remicade (infliximab), which had been approved for Crohn's disease in 1998 and later became one of the world's best-selling biologic drugs.

Key facts

Announced Jul 21, 1999
Closed Oct 06, 1999
Deal value $4.9B
Deal type Acquisition/Merger
Therapeutic area Gastroenterology, Immunology
Indications Crohn's Disease, Rheumatoid Arthritis
Key assets Remicade (infliximab), ReoPro (abciximab)
Mechanism Anti-TNF-alpha monoclonal antibody

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals